|
 The United States in recent weeks has made deals to acquire hundreds
of millions of doses of potential COVID-19 vaccines from several
companies as part of its Operation Warp Speed program, which aims to
deliver a vaccine in the country by the end of the year.
Moderna's price per dose comes to around $30.50 per person for a two
dose regimen.
With the exception of its deal with AstraZeneca, which offered a
lower price per drug in exchange for upfront research and
development costs, all the deals price COVID-19 vaccines between $20
to $42 for a two dose course of treatment.
Moderna's vaccine candidate, mRNA-1273, is one of the few that have
already advanced to the final stage of testing and is on track to be
completed in September, the company said this month.
Moderna's deal with the U.S. only pays out in full if the drugmaker
hits certain unspecific timing benchmarks for vaccine delivery.
The United States has advanced purchase agreements with Johnson &
Johnson <JNJ.N>, AstraZeneca Plc <AZN.L>, Pfizer Inc <PFIZ.NS> and
BioNTech SE <22UAy.F>, and Sanofi SA <SASY.PA> and GlaxoSmithKline
Plc <GSK.L> for their respective vaccine candidates.
[to top of second column] |
The agreements would lock in more than 500 million doses of COVID-19 vaccine for
the U.S., assuming that the companies involved receive regulatory approval. Some
deals also give the United States an option to purchase additional doses.
The U.S. government previously gave Moderna around $1 billion to fund its
research efforts, bringing total U.S. funding to around $2.5 billion.
Other countries, including Japan, the United Kingdom and Canada, have forged
similar deals with drugmakers.
(Reporting by Jeff Mason and Carl O'Donnell; Editing by Peter Henderson, Chris
Reese and Tom Brown)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
 |
